Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up

Background First Nations Peoples of Australia are disproportionally affected by hepatitis C (HCV) infection. Through a prospective study we evaluated the outcome of direct-acting antiviral (DAA) therapy among First Nations Peoples with HCV infection. Methods Adults who initiated DAA therapy at one o...

Full description

Saved in:
Bibliographic Details
Published inBMC gastroenterology Vol. 22; no. 1; pp. 1 - 10
Main Authors Clark, Paul J., Valery, Patricia C., Ward, James, Strasser, Simone I., Weltman, Martin, Thompson, Alexander, Levy, Miriam T., Leggett, Barbara, Zekry, Amany, Rong, Julian, Angus, Peter, George, Jacob, Bollipo, Steven, McGarity, Bruce, Sievert, William, Macquillan, Gerry, Tse, Edmund, Nicoll, Amanda, Wade, Amanda, Chu, Geoff, Harding, Damian, Cheng, Wendy, Farrell, Geoff, Roberts, Stuart K.
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 11.07.2022
BioMed Central
BMC
Subjects
Age
Analysis
Antiviral agents
Antiviral drugs
Australian aborigines
Comorbidity
Control
Data linkage
Dosage and administration
Fibrosis
Gastroenterology
Health aspects
Hepatitis C
Hepatitis C virus
Hypertension
Identification and classification
Infections
Liver diseases
Liver fibrosis
Liver function tests
Loss to follow-up
Medical record linkage
Medical records
Mental disorders
Mental health
Mortality
Narcotics
Patients
Prevention
Sustained viral response
Australia
Online AccessGet full text
ISSN1471-230X
1471-230X
DOI10.1186/s12876-022-02416-5

Cover

Abstract Background First Nations Peoples of Australia are disproportionally affected by hepatitis C (HCV) infection. Through a prospective study we evaluated the outcome of direct-acting antiviral (DAA) therapy among First Nations Peoples with HCV infection. Methods Adults who initiated DAA therapy at one of 26 hospitals across Australia, 2016-2019 were included in the study. Clinical data were obtained from medical records and the Pharmaceutical and Medicare Benefits Schemes. Outcomes included sustained virologic response (SVR) and loss to follow-up (LTFU). A multivariable analysis assessed factors associated with LTFU. Results Compared to non-Indigenous Australians (n = 3206), First Nations Peoples (n = 89) were younger (p < 0.001), morel likely to reside in most disadvantaged (p = 0.002) and in regional/remote areas (p < 0.001), and had similar liver disease severity. Medicines for mental health conditions were most commonly dispensed among First Nations Peoples (55.2% vs. 42.8%; p = 0.022). Of 2910 patients with follow-up data, both groups had high SVR rates (95.3% of First Nations Peoples vs. 93.2% of non-Indigenous patients; p = 0.51) and 'good' adherence (90.0% vs. 86.9%, respectively; p = 0.43). However, 28.1% of First Nations Peoples were LTFU vs. 11.2% of non-Indigenous patients (p < 0.001). Among First Nations Peoples, younger age (adj-OR = 0.93, 95% CI 0.87-0.99) and treatment initiation in 2018-2019 vs. 2016 (adj-OR = 5.14, 95% CI 1.23-21.36) predicted LTFU, while higher fibrosis score was associated with better engagement in HCV care (adj-OR = 0.71, 95% CI 0.50-0.99). Conclusions Our data showed that First Nations Peoples have an equivalent HCV cure rate, but higher rates of LTFU. Better strategies to increase engagement of First Nations Peoples with HCV care are needed. Keywords: Sustained viral response, Liver fibrosis, Data linkage, Loss to follow-up
AbstractList First Nations Peoples of Australia are disproportionally affected by hepatitis C (HCV) infection. Through a prospective study we evaluated the outcome of direct-acting antiviral (DAA) therapy among First Nations Peoples with HCV infection.BACKGROUNDFirst Nations Peoples of Australia are disproportionally affected by hepatitis C (HCV) infection. Through a prospective study we evaluated the outcome of direct-acting antiviral (DAA) therapy among First Nations Peoples with HCV infection.Adults who initiated DAA therapy at one of 26 hospitals across Australia, 2016-2019 were included in the study. Clinical data were obtained from medical records and the Pharmaceutical and Medicare Benefits Schemes. Outcomes included sustained virologic response (SVR) and loss to follow-up (LTFU). A multivariable analysis assessed factors associated with LTFU.METHODSAdults who initiated DAA therapy at one of 26 hospitals across Australia, 2016-2019 were included in the study. Clinical data were obtained from medical records and the Pharmaceutical and Medicare Benefits Schemes. Outcomes included sustained virologic response (SVR) and loss to follow-up (LTFU). A multivariable analysis assessed factors associated with LTFU.Compared to non-Indigenous Australians (n = 3206), First Nations Peoples (n = 89) were younger (p < 0.001), morel likely to reside in most disadvantaged (p = 0.002) and in regional/remote areas (p < 0.001), and had similar liver disease severity. Medicines for mental health conditions were most commonly dispensed among First Nations Peoples (55.2% vs. 42.8%; p = 0.022). Of 2910 patients with follow-up data, both groups had high SVR rates (95.3% of First Nations Peoples vs. 93.2% of non-Indigenous patients; p = 0.51) and 'good' adherence (90.0% vs. 86.9%, respectively; p = 0.43). However, 28.1% of First Nations Peoples were LTFU vs. 11.2% of non-Indigenous patients (p < 0.001). Among First Nations Peoples, younger age (adj-OR = 0.93, 95% CI 0.87-0.99) and treatment initiation in 2018-2019 vs. 2016 (adj-OR = 5.14, 95% CI 1.23-21.36) predicted LTFU, while higher fibrosis score was associated with better engagement in HCV care (adj-OR = 0.71, 95% CI 0.50-0.99).RESULTSCompared to non-Indigenous Australians (n = 3206), First Nations Peoples (n = 89) were younger (p < 0.001), morel likely to reside in most disadvantaged (p = 0.002) and in regional/remote areas (p < 0.001), and had similar liver disease severity. Medicines for mental health conditions were most commonly dispensed among First Nations Peoples (55.2% vs. 42.8%; p = 0.022). Of 2910 patients with follow-up data, both groups had high SVR rates (95.3% of First Nations Peoples vs. 93.2% of non-Indigenous patients; p = 0.51) and 'good' adherence (90.0% vs. 86.9%, respectively; p = 0.43). However, 28.1% of First Nations Peoples were LTFU vs. 11.2% of non-Indigenous patients (p < 0.001). Among First Nations Peoples, younger age (adj-OR = 0.93, 95% CI 0.87-0.99) and treatment initiation in 2018-2019 vs. 2016 (adj-OR = 5.14, 95% CI 1.23-21.36) predicted LTFU, while higher fibrosis score was associated with better engagement in HCV care (adj-OR = 0.71, 95% CI 0.50-0.99).Our data showed that First Nations Peoples have an equivalent HCV cure rate, but higher rates of LTFU. Better strategies to increase engagement of First Nations Peoples with HCV care are needed.CONCLUSIONSOur data showed that First Nations Peoples have an equivalent HCV cure rate, but higher rates of LTFU. Better strategies to increase engagement of First Nations Peoples with HCV care are needed.
Background First Nations Peoples of Australia are disproportionally affected by hepatitis C (HCV) infection. Through a prospective study we evaluated the outcome of direct-acting antiviral (DAA) therapy among First Nations Peoples with HCV infection. Methods Adults who initiated DAA therapy at one of 26 hospitals across Australia, 2016-2019 were included in the study. Clinical data were obtained from medical records and the Pharmaceutical and Medicare Benefits Schemes. Outcomes included sustained virologic response (SVR) and loss to follow-up (LTFU). A multivariable analysis assessed factors associated with LTFU. Results Compared to non-Indigenous Australians (n = 3206), First Nations Peoples (n = 89) were younger (p < 0.001), morel likely to reside in most disadvantaged (p = 0.002) and in regional/remote areas (p < 0.001), and had similar liver disease severity. Medicines for mental health conditions were most commonly dispensed among First Nations Peoples (55.2% vs. 42.8%; p = 0.022). Of 2910 patients with follow-up data, both groups had high SVR rates (95.3% of First Nations Peoples vs. 93.2% of non-Indigenous patients; p = 0.51) and 'good' adherence (90.0% vs. 86.9%, respectively; p = 0.43). However, 28.1% of First Nations Peoples were LTFU vs. 11.2% of non-Indigenous patients (p < 0.001). Among First Nations Peoples, younger age (adj-OR = 0.93, 95% CI 0.87-0.99) and treatment initiation in 2018-2019 vs. 2016 (adj-OR = 5.14, 95% CI 1.23-21.36) predicted LTFU, while higher fibrosis score was associated with better engagement in HCV care (adj-OR = 0.71, 95% CI 0.50-0.99). Conclusions Our data showed that First Nations Peoples have an equivalent HCV cure rate, but higher rates of LTFU. Better strategies to increase engagement of First Nations Peoples with HCV care are needed. Keywords: Sustained viral response, Liver fibrosis, Data linkage, Loss to follow-up
First Nations Peoples of Australia are disproportionally affected by hepatitis C (HCV) infection. Through a prospective study we evaluated the outcome of direct-acting antiviral (DAA) therapy among First Nations Peoples with HCV infection. Adults who initiated DAA therapy at one of 26 hospitals across Australia, 2016-2019 were included in the study. Clinical data were obtained from medical records and the Pharmaceutical and Medicare Benefits Schemes. Outcomes included sustained virologic response (SVR) and loss to follow-up (LTFU). A multivariable analysis assessed factors associated with LTFU. Compared to non-Indigenous Australians (n = 3206), First Nations Peoples (n = 89) were younger (p < 0.001), morel likely to reside in most disadvantaged (p = 0.002) and in regional/remote areas (p < 0.001), and had similar liver disease severity. Medicines for mental health conditions were most commonly dispensed among First Nations Peoples (55.2% vs. 42.8%; p = 0.022). Of 2910 patients with follow-up data, both groups had high SVR rates (95.3% of First Nations Peoples vs. 93.2% of non-Indigenous patients; p = 0.51) and 'good' adherence (90.0% vs. 86.9%, respectively; p = 0.43). However, 28.1% of First Nations Peoples were LTFU vs. 11.2% of non-Indigenous patients (p < 0.001). Among First Nations Peoples, younger age (adj-OR = 0.93, 95% CI 0.87-0.99) and treatment initiation in 2018-2019 vs. 2016 (adj-OR = 5.14, 95% CI 1.23-21.36) predicted LTFU, while higher fibrosis score was associated with better engagement in HCV care (adj-OR = 0.71, 95% CI 0.50-0.99). Our data showed that First Nations Peoples have an equivalent HCV cure rate, but higher rates of LTFU. Better strategies to increase engagement of First Nations Peoples with HCV care are needed.
Background First Nations Peoples of Australia are disproportionally affected by hepatitis C (HCV) infection. Through a prospective study we evaluated the outcome of direct-acting antiviral (DAA) therapy among First Nations Peoples with HCV infection. Methods Adults who initiated DAA therapy at one of 26 hospitals across Australia, 2016–2019 were included in the study. Clinical data were obtained from medical records and the Pharmaceutical and Medicare Benefits Schemes. Outcomes included sustained virologic response (SVR) and loss to follow-up (LTFU). A multivariable analysis assessed factors associated with LTFU. Results Compared to non-Indigenous Australians (n = 3206), First Nations Peoples (n = 89) were younger (p < 0.001), morel likely to reside in most disadvantaged (p = 0.002) and in regional/remote areas (p < 0.001), and had similar liver disease severity. Medicines for mental health conditions were most commonly dispensed among First Nations Peoples (55.2% vs. 42.8%; p = 0.022). Of 2910 patients with follow-up data, both groups had high SVR rates (95.3% of First Nations Peoples vs. 93.2% of non-Indigenous patients; p = 0.51) and ‘good’ adherence (90.0% vs. 86.9%, respectively; p = 0.43). However, 28.1% of First Nations Peoples were LTFU vs. 11.2% of non-Indigenous patients (p < 0.001). Among First Nations Peoples, younger age (adj-OR = 0.93, 95% CI 0.87–0.99) and treatment initiation in 2018–2019 vs. 2016 (adj-OR = 5.14, 95% CI 1.23–21.36) predicted LTFU, while higher fibrosis score was associated with better engagement in HCV care (adj-OR = 0.71, 95% CI 0.50–0.99). Conclusions Our data showed that First Nations Peoples have an equivalent HCV cure rate, but higher rates of LTFU. Better strategies to increase engagement of First Nations Peoples with HCV care are needed.
Abstract Background First Nations Peoples of Australia are disproportionally affected by hepatitis C (HCV) infection. Through a prospective study we evaluated the outcome of direct-acting antiviral (DAA) therapy among First Nations Peoples with HCV infection. Methods Adults who initiated DAA therapy at one of 26 hospitals across Australia, 2016–2019 were included in the study. Clinical data were obtained from medical records and the Pharmaceutical and Medicare Benefits Schemes. Outcomes included sustained virologic response (SVR) and loss to follow-up (LTFU). A multivariable analysis assessed factors associated with LTFU. Results Compared to non-Indigenous Australians (n = 3206), First Nations Peoples (n = 89) were younger (p < 0.001), morel likely to reside in most disadvantaged (p = 0.002) and in regional/remote areas (p < 0.001), and had similar liver disease severity. Medicines for mental health conditions were most commonly dispensed among First Nations Peoples (55.2% vs. 42.8%; p = 0.022). Of 2910 patients with follow-up data, both groups had high SVR rates (95.3% of First Nations Peoples vs. 93.2% of non-Indigenous patients; p = 0.51) and ‘good’ adherence (90.0% vs. 86.9%, respectively; p = 0.43). However, 28.1% of First Nations Peoples were LTFU vs. 11.2% of non-Indigenous patients (p < 0.001). Among First Nations Peoples, younger age (adj-OR = 0.93, 95% CI 0.87–0.99) and treatment initiation in 2018–2019 vs. 2016 (adj-OR = 5.14, 95% CI 1.23–21.36) predicted LTFU, while higher fibrosis score was associated with better engagement in HCV care (adj-OR = 0.71, 95% CI 0.50–0.99). Conclusions Our data showed that First Nations Peoples have an equivalent HCV cure rate, but higher rates of LTFU. Better strategies to increase engagement of First Nations Peoples with HCV care are needed.
ArticleNumber 339
Audience Academic
Author Cheng, Wendy
Levy, Miriam T.
Tse, Edmund
Harding, Damian
Macquillan, Gerry
Roberts, Stuart K.
Valery, Patricia C.
Farrell, Geoff
Thompson, Alexander
Nicoll, Amanda
Weltman, Martin
Leggett, Barbara
McGarity, Bruce
Strasser, Simone I.
Rong, Julian
Sievert, William
Bollipo, Steven
Clark, Paul J.
Zekry, Amany
Chu, Geoff
George, Jacob
Ward, James
Angus, Peter
Wade, Amanda
Author_xml – sequence: 1
  givenname: Paul J.
  surname: Clark
  fullname: Clark, Paul J.
– sequence: 2
  givenname: Patricia C.
  orcidid: 0000-0002-8823-3006
  surname: Valery
  fullname: Valery, Patricia C.
– sequence: 3
  givenname: James
  orcidid: 0000-0002-2892-4542
  surname: Ward
  fullname: Ward, James
– sequence: 4
  givenname: Simone I.
  orcidid: 0000-0001-6374-1525
  surname: Strasser
  fullname: Strasser, Simone I.
– sequence: 5
  givenname: Martin
  surname: Weltman
  fullname: Weltman, Martin
– sequence: 6
  givenname: Alexander
  surname: Thompson
  fullname: Thompson, Alexander
– sequence: 7
  givenname: Miriam T.
  surname: Levy
  fullname: Levy, Miriam T.
– sequence: 8
  givenname: Barbara
  surname: Leggett
  fullname: Leggett, Barbara
– sequence: 9
  givenname: Amany
  surname: Zekry
  fullname: Zekry, Amany
– sequence: 10
  givenname: Julian
  surname: Rong
  fullname: Rong, Julian
– sequence: 11
  givenname: Peter
  surname: Angus
  fullname: Angus, Peter
– sequence: 12
  givenname: Jacob
  surname: George
  fullname: George, Jacob
– sequence: 13
  givenname: Steven
  surname: Bollipo
  fullname: Bollipo, Steven
– sequence: 14
  givenname: Bruce
  surname: McGarity
  fullname: McGarity, Bruce
– sequence: 15
  givenname: William
  surname: Sievert
  fullname: Sievert, William
– sequence: 16
  givenname: Gerry
  surname: Macquillan
  fullname: Macquillan, Gerry
– sequence: 17
  givenname: Edmund
  surname: Tse
  fullname: Tse, Edmund
– sequence: 18
  givenname: Amanda
  surname: Nicoll
  fullname: Nicoll, Amanda
– sequence: 19
  givenname: Amanda
  surname: Wade
  fullname: Wade, Amanda
– sequence: 20
  givenname: Geoff
  surname: Chu
  fullname: Chu, Geoff
– sequence: 21
  givenname: Damian
  surname: Harding
  fullname: Harding, Damian
– sequence: 22
  givenname: Wendy
  surname: Cheng
  fullname: Cheng, Wendy
– sequence: 23
  givenname: Geoff
  surname: Farrell
  fullname: Farrell, Geoff
– sequence: 24
  givenname: Stuart K.
  surname: Roberts
  fullname: Roberts, Stuart K.
BookMark eNp9kl2P1CAUhhuzxv3QP-AViTfedAVaCnhhMpnsupts1PgV7wilpzNMaOkCXeONv11mZo3OxhjSQOF9n5Zz3tPiaPQjFMVzgs8JEc2rSKjgTYkpzU9NmpI9Kk5IzUlJK_zt6K_1cXEa4wZjwgWtnhTHFRMUC4ZPip9XMOlkk41oiVIAnQYYE_JzMn6AiHof0GKOKWhn9YgubYgJvcsOP0b0AfzkIL5GcDvbO-22zk9fP6KgE6B2TmhtV2sIu_eIfI-cjxEln6nO-e_lPD0tHvfaRXh2P58VXy4vPi-vypv3b6-Xi5vSsBqnkmsK1HQ17tqq62toBe-I0JgS3WrJcCeNIdg0rYZKAgGOqeSm45LoRjJKqrPies_tvN6oKdhBhx_Ka6t2Gz6slA7JGgfKcNaYvqemqWUtdd92WFQt7mtiGNeVyKw3e9Y0twN0Jt86V-cAengy2rVa-TslKWeYyAx4eQ8I_naGmNRgowHn9Ah-joo2QmLGBdn-94sH0o2fw5hLlVWS1Awz0fxRrXIPlB17n79rtlC14ATjilLCs-r8H6o8OhisydHqbd4_MIi9wYTctwC9MjbtWp-N1imC1TaHap9DlXOodjlULFvpA-vv8vzH9AsgguEr
CitedBy_id crossref_primary_10_1111_dar_13914
crossref_primary_10_1111_jgh_16440
crossref_primary_10_1016_j_drugpo_2024_104335
crossref_primary_10_1186_s12916_024_03699_z
crossref_primary_10_3390_v16060979
Cites_doi 10.1071/AH09835
10.1016/j.jhep.2018.04.013
10.1016/j.eclinm.2019.05.007
10.1186/1472-6963-13-460
10.1111/1753-6405.12888
10.1136/bmjopen-2017-020196
10.1016/j.jhep.2019.04.014
10.1186/s12954-018-0209-y
10.1080/00048670701332953
10.1097/NMD.0b013e3181c7e7bc
10.1007/s10620-022-07483-y
10.1071/AH19194
10.1111/dar.12320
10.1111/jvh.13162
10.1071/AH20011
10.1002/hep4.1826
10.1002/hep.21178
10.1016/j.drugpo.2017.07.021
10.1136/bmjopen-2017-021122
10.1016/S2055-6640(20)30270-3
ContentType Journal Article
Copyright COPYRIGHT 2022 BioMed Central Ltd.
2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022. The Author(s).
The Author(s) 2022
Copyright_xml – notice: COPYRIGHT 2022 BioMed Central Ltd.
– notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022. The Author(s).
– notice: The Author(s) 2022
DBID AAYXX
CITATION
3V.
7QP
7QR
7T5
7X7
7XB
88E
8FD
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FR3
FYUFA
GHDGH
H94
K9.
M0S
M1P
P64
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12876-022-02416-5
DatabaseName CrossRef
ProQuest Central (Corporate)
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Technology Research Database
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
PML(ProQuest Medical Library)
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
Chemoreception Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic


Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-230X
EndPage 10
ExternalDocumentID oai_doaj_org_article_c756cff2c64949afbd083b0f41c57a38
PMC9275019
A710032217
10_1186_s12876_022_02416_5
GeographicLocations Australia
GeographicLocations_xml – name: Australia
GrantInformation_xml – fundername: ;
– fundername: ;
  grantid: (2018-19/05156)
GroupedDBID ---
0R~
23N
2WC
53G
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
PMFND
3V.
7QP
7QR
7T5
7XB
8FD
8FK
AZQEC
DWQXO
FR3
H94
K9.
P64
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c540t-7a2e2cd40db3df4eb87d18a021aba950d9cc10c6bae39e1e70297cd791a695213
IEDL.DBID M48
ISSN 1471-230X
IngestDate Wed Aug 27 01:29:23 EDT 2025
Thu Aug 21 14:36:54 EDT 2025
Thu Aug 07 14:52:50 EDT 2025
Fri Jul 25 20:52:04 EDT 2025
Tue Jun 17 21:29:37 EDT 2025
Tue Jun 10 20:23:39 EDT 2025
Tue Jul 01 04:12:08 EDT 2025
Thu Apr 24 23:13:05 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c540t-7a2e2cd40db3df4eb87d18a021aba950d9cc10c6bae39e1e70297cd791a695213
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-2892-4542
0000-0001-6374-1525
0000-0002-8823-3006
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12876-022-02416-5
PMID 35820850
PQID 2691450586
PQPubID 44673
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_c756cff2c64949afbd083b0f41c57a38
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9275019
proquest_miscellaneous_2689057811
proquest_journals_2691450586
gale_infotracmisc_A710032217
gale_infotracacademiconefile_A710032217
crossref_citationtrail_10_1186_s12876_022_02416_5
crossref_primary_10_1186_s12876_022_02416_5
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-07-11
PublicationDateYYYYMMDD 2022-07-11
PublicationDate_xml – month: 07
  year: 2022
  text: 2022-07-11
  day: 11
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle BMC gastroenterology
PublicationYear 2022
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References 2416_CR16
KL Sloan (2416_CR11) 2003; 41
SW Majoni (2416_CR21) 2021; 45
K Institute (2416_CR17) 2018
A Rashidi (2416_CR20) 2020; 44
2416_CR2
EE Powell (2416_CR4) 2019; 11
C Treloar (2416_CR5) 2018; 15
2416_CR6
M Hopwood (2416_CR26) 2015
NL Pratt (2416_CR12) 2018; 8
S Shahid (2416_CR22) 2011; 35
S Bloom (2416_CR10) 2018; 69
S Shahid (2416_CR23) 2013; 13
M Alavi (2416_CR3) 2019; 71
BL Norton (2416_CR15) 2017; 47
VA Ypinazar (2416_CR25) 2007; 41
P Lakhan (2416_CR18) 2019; 43
Australian Institute of Health and Welfare (AIHW) (2416_CR27) 2017
SC Ratzan (2416_CR31) 2000
K Institute (2416_CR1) 2020
A Lee (2416_CR14) 2018; 4
BF Nasir (2416_CR24) 2018; 8
Australian Institute of Health and Welfare (AIHW) (2416_CR7) 2004
Australian Institute of Health and Welfare (AIHW) (2416_CR19) 2018
J Bryant (2416_CR28) 2016; 35
Commonwealth of Australia (2416_CR32) 2018
RK Sterling (2416_CR9) 2006; 43
M Lu (2416_CR13) 2019; 26
R Parker (2416_CR29) 2010; 198
M Toombs (2416_CR30) 2013
Australian Bureau of Statistics (ABS) (2416_CR8) 2008
References_xml – volume-title: Cancer in Aboriginal & Torres Strait Islander people of Australia
  year: 2018
  ident: 2416_CR19
– volume: 35
  start-page: 235
  year: 2011
  ident: 2416_CR22
  publication-title: Aust Health Rev
  doi: 10.1071/AH09835
– volume: 69
  start-page: 575
  year: 2018
  ident: 2416_CR10
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2018.04.013
– volume: 11
  start-page: 44
  year: 2019
  ident: 2416_CR4
  publication-title: EClinicalMedicine
  doi: 10.1016/j.eclinm.2019.05.007
– volume: 13
  start-page: 460
  year: 2013
  ident: 2416_CR23
  publication-title: BMC Health Serv Res
  doi: 10.1186/1472-6963-13-460
– volume-title: Fifth national hepatitis C strategy: 2018–2022
  year: 2018
  ident: 2416_CR32
– start-page: 225
  volume-title: Indigenous Australians and health: the Wombat in the room
  year: 2013
  ident: 2416_CR30
– volume: 43
  start-page: 228
  year: 2019
  ident: 2416_CR18
  publication-title: Aust N Z J Public Health
  doi: 10.1111/1753-6405.12888
– volume-title: National drug strategy household survey 2016: detailed findings
  year: 2017
  ident: 2416_CR27
– volume: 8
  year: 2018
  ident: 2416_CR24
  publication-title: BMJ Open
  doi: 10.1136/bmjopen-2017-020196
– volume-title: National Library of Medicine current bibliographies in medicine: health literacy
  year: 2000
  ident: 2416_CR31
– ident: 2416_CR2
– volume: 71
  start-page: 281
  year: 2019
  ident: 2416_CR3
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2019.04.014
– volume: 15
  start-page: 5
  year: 2018
  ident: 2416_CR5
  publication-title: Harm Reduct J
  doi: 10.1186/s12954-018-0209-y
– volume: 41
  start-page: 467
  year: 2007
  ident: 2416_CR25
  publication-title: Aust N Z J Psychiatry
  doi: 10.1080/00048670701332953
– volume: 198
  start-page: 3
  year: 2010
  ident: 2416_CR29
  publication-title: J Nerv Ment Dis
  doi: 10.1097/NMD.0b013e3181c7e7bc
– ident: 2416_CR6
  doi: 10.1007/s10620-022-07483-y
– volume: 44
  start-page: 755
  year: 2020
  ident: 2416_CR20
  publication-title: Aust Health Rev
  doi: 10.1071/AH19194
– volume: 35
  start-page: 447
  year: 2016
  ident: 2416_CR28
  publication-title: Drug Alcohol Rev
  doi: 10.1111/dar.12320
– volume-title: Census of Population and Housing: Socio-economic Indexes for Areas (SEIFA), Australia, 2006
  year: 2008
  ident: 2416_CR8
– volume: 26
  start-page: 1210
  year: 2019
  ident: 2416_CR13
  publication-title: J Viral Hepat
  doi: 10.1111/jvh.13162
– volume: 45
  start-page: 185
  year: 2021
  ident: 2416_CR21
  publication-title: Aust Health Rev
  doi: 10.1071/AH20011
– volume-title: Barriers to, and enablers of, embedding the management and care of viral hepatitis in primary care settings
  year: 2015
  ident: 2416_CR26
– volume-title: National update on HIV, viral hepatitis and sexually transmissible infections in Australia: 2009–2018
  year: 2020
  ident: 2416_CR1
– volume-title: Bloodborne viral and sexually transmissible infections in Aboriginal and Torres Strait Islander people: annual surveillance report 2018
  year: 2018
  ident: 2416_CR17
– volume-title: Rural, regional and remote health: a guide to remoteness classifications
  year: 2004
  ident: 2416_CR7
– ident: 2416_CR16
  doi: 10.1002/hep4.1826
– volume: 43
  start-page: 1317
  year: 2006
  ident: 2416_CR9
  publication-title: Hepatology
  doi: 10.1002/hep.21178
– volume: 47
  start-page: 196
  year: 2017
  ident: 2416_CR15
  publication-title: Int J Drug Policy
  doi: 10.1016/j.drugpo.2017.07.021
– volume: 8
  year: 2018
  ident: 2416_CR12
  publication-title: BMJ Open
  doi: 10.1136/bmjopen-2017-021122
– volume: 41
  start-page: 761
  year: 2003
  ident: 2416_CR11
  publication-title: Med Care
– volume: 4
  start-page: 160
  year: 2018
  ident: 2416_CR14
  publication-title: J Virus Erad
  doi: 10.1016/S2055-6640(20)30270-3
SSID ssj0017823
Score 2.347671
Snippet Background First Nations Peoples of Australia are disproportionally affected by hepatitis C (HCV) infection. Through a prospective study we evaluated the...
First Nations Peoples of Australia are disproportionally affected by hepatitis C (HCV) infection. Through a prospective study we evaluated the outcome of...
Abstract Background First Nations Peoples of Australia are disproportionally affected by hepatitis C (HCV) infection. Through a prospective study we evaluated...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1
SubjectTerms Age
Analysis
Antiviral agents
Antiviral drugs
Australian aborigines
Comorbidity
Control
Data linkage
Dosage and administration
Fibrosis
Gastroenterology
Health aspects
Hepatitis C
Hepatitis C virus
Hypertension
Identification and classification
Infections
Liver diseases
Liver fibrosis
Liver function tests
Loss to follow-up
Medical record linkage
Medical records
Mental disorders
Mental health
Mortality
Narcotics
Patients
Prevention
Sustained viral response
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9UwEA-yB_EifmJ1lQiCBynb9CMf3tbFx0NYEXVlbyGf7INHu9qWve3f7kza99wq6MVDD20-SDIzmUkz8xtCXlWxaKQ0AeTb-7yOjcytL1wO34umDJXnEgOFTz_y9Vn94bw5v5HqC33CJnjgaeGOnGi4i7F0HHFUTISeZGWLWDPXCFOlMF_QebvD1Hx_AHqv2oXISH7Uwy4s0Nm2hAdMkLxZqKGE1v_nnvy7n-QNxbO6R-7OFiM9nkZ6n9wK7QNy-3S-E39IrtcBvaKHTU9P6N5vnHbjAMwUegpWKf31R4OuNmDv0QkOu6efkgN5_5aG7-MGmA5bfvn2mSKABLXjQC-SH0h672kX6RZmQ4cOet1uu6t8vHxEzlbvv56s8zmrQu7AOhtyYcpQOl8X3lY-1sFK4Zk0oOuNNaopvHKOFY5bEyoVWBCY3sp5oZjhCpR99ZgctF0bnhBaeBl8kEFG7oAetbWl4LGuojABM-RlhO0WWbsZchwzX2x1OnpIrifCaCCMToTR0ObNvs3lBLjx19rvkHb7mgiWnT4AC-mZhfS_WCgjr5HyGkUahufMHJkAk0RwLH2MCEiw8TGRkcNFTRBFtyze8Y6et4Jel1yxGhZD8oy83BdjS3Rva0M3Yh2pwHCWjGVELHhuMbNlSbu5SHDgCiH6mXr6P5biGblTJikROWOH5GD4MYbnYHUN9kUSsJ-CJiu3
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bi9QwFA66gvgiXrG6SgTBBynb9JKkvsi6OAzCiqgr8xbSXHYHhnZ22-Kbv91zMpmuVdiHPkyTtM2ca9Mv3yHkTeGzSkrtwL6tTUtfybSxmUnhfFblrrBc4kbh0y98eVZ-XlWruODWR1jl3icGR207g2vkRzmvWQnhWvIP28sUq0bh19VYQuM2uYPUZQjpEqvphYtB9Cv2G2UkP-rBFwuE3OZwQCKSVrNgFDj7__fM_6Il_wo_iwfkfswb6fFO0A_JLdc-IndP45fxx-T30iE2elj39IRO6HHajQNMz_UUclN6va5BF2vI-uiOFLunXwOMvH9P3eW4BtXDkd9_fqNII0GbcaAXAQ0Sfve083QDs6FDB1fdbLpf6bh9Qs4Wn36cLNNYWyE1kKMNqdC5y40tM9sU1peukcIyqSHi60bXVWZrY1hmeKNdUTvmBBa5MlbUTPMaQn7xlBy0XeueEZpZ6ayTTnpuSmbKpskF92XhhXZYJy8hbP8nKxOJx7H-xUaFFxDJ1U4wCgSjgmAUjHk3jdnuaDdu7P0RZTf1RMrscKK7OlfRApURFTfe54YjIY_2oJKyaDIPj1wJXciEvEXJKzRseDyj4_4EmCRSZKlj5EEC98dEQg5nPcEgzbx5rzsqOoReXatvQl5PzTgSQW6t60bsI2tInyVjCREznZvNbN7Sri8CKXiNRP2sfn7zzV-Qe3nQf5EydkgOhqvRvYSsamheBdP5Ayx6Irw
  priority: 102
  providerName: ProQuest
Title Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up
URI https://www.proquest.com/docview/2691450586
https://www.proquest.com/docview/2689057811
https://pubmed.ncbi.nlm.nih.gov/PMC9275019
https://doaj.org/article/c756cff2c64949afbd083b0f41c57a38
Volume 22
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBf9gNKX0X2xbF3QYLCH4c3yhyQPxmhKQxiklGwZYS9CluQ1EOI2tun2sr99d4qTzlvZwx5sbEtnLN2d9LN9-h0hL-MiTKXUDvzb2iApUhnkNjQBXA_TyMWWS1woPD7no2nycZbOdsgm3VHbgdWdr3aYT2q6Wrz5fv3jAzj8e-_wkr-tYIwVGEobwQYAI0h3yT4cCHTUcXL7VwFmw3izcOZOuUNygCtHkcatM095Ov-_B-0_Ayl_m5mGR-ReCynpydoG7pMdt3xADsbtT_OH5OfIYdh0Pa_oKd0GltOyqcHaXEUBttLbTx50OAdASNd82RW98BHm1Tvqrps5WCVKfvoyocgwQfOmppc-UMSfV7Qs6AJaQ-sS7rpYlDdBc_WITIdnn09HQZt2ITAA3-pA6MhFxiahzWNbJC6XwjKpAQzoXGdpaDNjWGh4rl2cOeYE5r8yVmRM8wzQQPyY7C3LpXtCaGils046WXCTMJPkeSR4kcSF0A5T6PUI23SyMi0nOabGWCj_biK5WutIgY6U15ECmddbmas1I8c_aw9Qd9uayKbtL5Srb6p1TmVEyk1RRIYjV48uwFplnIcFPHIqdCx75BVqXqEVwuMZ3S5dgEYie5Y6QYokGBmZ6JHjTk3wVdMt3tiO2pi6injGEugMyXvkxbYYJTH-benKBuvIDJC1ZKxHRMfmOi3rliznl54vPEMOf5Y9_W_JZ-Qw8l4iAsaOyV69atxzwGJ13ie7Yib6ZH9wdn4x6fsvGn3vdLCfDL7-Aq8zN7M
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKVgIuiKcIFDASiAOKGudhO0gItaWrLe2uqtKi3oxjO3Sl1WbbJKq48JP4jcxkky0BqbceckhsJ7HnaXv8DSFvojxIpNQO5NtaP84T6Wc2MD48D5LQRZZLPCg8nvDRSfzlNDldI7-7szAYVtnpxEZR28LgGvlmyFMWg7mW_NPi3MesUbi72qXQWLLFvvt5CVO28uPeZ6Dv2zAc7h7vjPw2q4BvwDupfKFDFxobBzaLbB67TArLpAZbpzOdJoFNjWGB4Zl2UeqYE5jeyViRMs1TMHYRvPcWWY8jmMoMyPr27uTwaLVvAfY26o7mSL5ZgvYXGOQbwgWuj5_0zF-TJeB_W_BvfOZfBm94n9xrPVW6tWStB2TNzR-S2-N2L_4R-TVyGI1dTUu6Q1fx6rSoKxhQV1LwhunVSgodTsHPpEsY7pIeNoHr5QfqzuspMDu2_PrtiCJwBc3qip418SfNfUmLnM6gN7Qq4K2zWXHp14vH5ORGxv0JGcyLuXtKaGCls046mXMTMxNnWSh4Hke50A4z83mEdYOsTAt1jhk3ZqqZ8kiuloRRQBjVEEZBm_erNosl0Me1tbeRdquaCNLdPCgufqhW5pURCTd5HhqOEEA6ByGQURbk8MuJ0JH0yDukvEJVAr9ndHsiAjqJoFxqC5GXQOEy4ZGNXk1QAaZf3PGOalVQqa4ExiOvV8XYEsPq5q6osY5MwWGXjHlE9Hiu17N-yXx61sCQp5gagKXPrv_4K3JndDw-UAd7k_3n5G7YyILwGdsgg-qidi_Ap6uyl60gUfL9pmX3DwxmYbM
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hepatitis+C+treatment+outcomes+for+Australian+First+Nations+Peoples%3A+equivalent+SVR+rate+but+higher+rates+of+loss+to+follow-up&rft.jtitle=BMC+gastroenterology&rft.au=Clark%2C+Paul+J.&rft.au=Valery%2C+Patricia+C.&rft.au=Ward%2C+James&rft.au=Strasser%2C+Simone+I.&rft.date=2022-07-11&rft.pub=BioMed+Central&rft.eissn=1471-230X&rft.volume=22&rft_id=info:doi/10.1186%2Fs12876-022-02416-5&rft_id=info%3Apmid%2F35820850&rft.externalDocID=PMC9275019
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-230X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-230X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-230X&client=summon